Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Organon, Pfizer Hope Hot Flashes Will Be Hot Market

This article was originally published in The Pink Sheet Daily

Executive Summary

Organon's 5HT2-antagonist Org 50018 is in Phase II/III development as an alternative to hormone therapy for treatment of hot flashes. Pfizer also has eyes on the market, licensing a University of Rochester patent that covers use of Lyrica.

You may also be interested in...



Pfizer Ends Asenapine Collaboration With Organon

Akzo Nobel unit will continue development of the Phase III antipsychotic as company moves forward with separation of its coatings and chemical division from its pharma business.

Pfizer Ends Asenapine Collaboration With Organon

Akzo Nobel unit will continue development of the Phase III antipsychotic as company moves forward with separation of its coatings and chemical division from its pharma business.

Organon Considering Partnership For Hormone Therapy Livial In U.S.

Organon is considering finding a partner to support the introduction of its hormone therapy Livial (tibolone) in the U.S

Topics

UsernamePublicRestriction

Register

PS078529

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel